Science

Gustavo Viani: Internal Mammary Node Spotlight – Does Therapeutic Irradiation Steal the Show?

Gustavo Viani/sbradioterapia.com.br

Feb 25, 2025, 08:33

Gustavo Viani: Internal Mammary Node Spotlight – Does Therapeutic Irradiation Steal the Show?

Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared a post on LinkedIn:

“Internal Mammary Node (IMN) Spotlight: Does Therapeutic Irradiation Steal the Show?

Target objective

Explore if IMN radiotherapy dose affects relapse (IMNR) and OS in breast cancer.

Methods

Case-control study (70 IMNR cases vs. 140 controls), BC Cancer cohort 2005-14, IMN doses calculated from CT (EQD2), ≥40 Gy as therapeutic, multivariable Fine-Gray and Cox analysis.

Results

radiotherapy ≥40 Gy low IMNR (HR=0.36, p=0.009) and high OS (HR=0.49, p=0.02)
Mastectomy (HR=2.11, p=0.02), larger tumors, and N+ high risk IMNR.

Clinical impact

IMN radiotherapy with therapeutic dose (≥40 Gy) is critical for controlling IMN and high OS in high-risk cases!”

“A matched case-control study of the relationship between radiation dose to the internal mammary lymph nodes and clinical outcomes in patients with and without internal mammary lymph node relapses”

Authors: Alan Nichol, Louise Wade, Lovedeep Gondara, Caroline Speers, Caroline Lohrisch et al.

Gustavo Viani: Internal Mammary Node Spotlight - Does Therapeutic Irradiation Steal the Show?

More posts featuring Gustavo Viani.

Alan Nichol cancer Caroline Lohrisch Caroline Speers Gustavo Viani IMN IMN radiotherapy IMNR Internal Mammary Node Louise Wade Lovedeep Gondara OncoDaily Oncology

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC